Skip to main content
Olwen Hahn, MD, Oncology, Chicago, IL

OlwenMHahnMD

Oncology Chicago, IL

Breast Cancer, Genitourinary Oncology, Hematologic Oncology

Associate Professor, University of Chicago

Dr. Hahn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Hahn's full profile

Already have an account?

  • Office

    5841 S. MARYLAND
    M/C 2115
    Chicago, IL 60637
    Phone+1 773-702-5381
    Fax+1 773-702-3163

Education & Training

  • University of Chicago
    University of ChicagoFellowship, Hematology and Medical Oncology, 2004 - 2007
  • University of Chicago
    University of ChicagoResidency, Internal Medicine, 2001 - 2004
  • Emory University School of Medicine
    Emory University School of MedicineClass of 2001

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 2004 - 2026
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised ...  
    Toni K Choueiri, Olwen Hahn, Thomas Olencki, Eric J Small, Shaker Dakhil, Darren R Feldman, European Journal of Cancer

Authored Content

  • Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival Update’ [Eur J Cancer 94 (May 2018) 115–125]September 2018
  • Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival UpdateApril 2018

Press Mentions

  • Bodybuilder’s Battle with Breast Cancer: “Emotionally I Was a Wreck.”
    Bodybuilder’s Battle with Breast Cancer: “Emotionally I Was a Wreck.”January 27th, 2022

Professional Memberships